Uncertain times are upon us, around the world, as we globally respond to the coronavirus (COVID-19) that is affecting us all on some level. Many members of our bladder cancer community are directing questions our way about how the this virus might affect their health and treatments. We will be answering many of these questions after consulting with theRead more
Blog
Dearest Friend, Uncertain times are upon us, around the world, as we globally respond to the coronavirus (COVID-19) that’s affecting us all on some level. For those of you diagnosed with bladder cancer, undergoing treatment, waiting for surgeries or trying to move forward with your lives post-cancer, we know that this can be an especiallyRead more
Dear Friend of Bladder Cancer Canada,Please help us understand what patients and caregivers think is important in bladder cancer research.Below is a link to a patient and caregiver survey that has been designed by our colleagues at the Bladder Cancer Advocacy Network in the USA. This survey has already been completed by many across the USA and we areRead more
(The following content is sourced from various sites advising on the coronavirus. For more information, please see the end of this article for additional resources. Photo Credit: CDC) As news of the coronavirus (COVID-19) continues to spread globally, many people have become concerned about contracting this disease. For cancer patients and survivors that have a compromisedRead more
IMPORTANT UPDATE – March 9, 2020 Bladder Cancer Canada (BCC) and its Medical Advisory Board were advised by Merck Canada in November 2019 that they would continue to face challenges in the supply of the TICE strain of Bacillus Calmette-Guerin (BCG) in Canada for 2020. As the only supplier of BCG in Canada, Merck established an allocation planRead more
Bladder Cancer Canada Position Statement on Canadian Bacillus Calmette-Guérin (BCG) Shortage Updated March 4, 2020 Bacillus Calmette-Guérin (BCG) has been the standard of care for many patients with non-muscle invasive bladder cancer for decades. Bladder Cancer Canada and our Medical Advisory Board have been advised by Merck Canada, that they anticipate a limited supply of BCGRead more
In a recent press release, Janssen Pharmaceutical Companies of Johnson & Johnson have announced that they have received approval from Health Canada for BALVERSA™ (erdafitinib), the first FGFR Kinase inhibitor for the treatment of patients with locally advanced or metastatic urothelial carcinoma with certain FGFR genetic alterations. Health Canada has approved the therapy on the conditionRead more